Arecor featured by the highly regarded industry publication, Scrip


Arecor Limited, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, is pleased to announce that a feature profile by the highly regarded industry publication, SCRIP, is now available for viewing.

This excellent feature came out shortly after the Company announced that it had filed a Clinical Trial Application (CTA) to conduct a Phase I study in Diabetes Type 1 patients of its ultra-rapid acting insulin product, AT247.   This novel formulation of prandial insulin is designed to deliver an acceleration of insulin absorption post injection and the filing represents a key and important milestone in the advancement of the Company’s proprietary portfolio for diabetes care.

Advancing today's therapies to enable healthier lives.

Arecor Therapeutics Plc